HIV, lenacapavir and Gilead Sciences

Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
HIV Protection in One Injection? Gilead’s Lenacapavir Could Be a Game-Changer!
A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations.
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year | After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate,
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an intramuscular injection given as two once-yearly formulations for pre-exposure prophylaxis (PrEP) in HIV prevention.
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This upward trajectory coincides with positive developments in its HIV treatment portfolio,
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
(Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
MedPage Today on MSN2d
Once-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly Dosing
A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
MIT Technology Review2d
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Managed Healthcare Executive2d
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
The Scientist3d
Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Queerty on MSN3d
A once-a-year PrEP injection? The results of the first clinical trial look promising
Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...